InvestorsHub Logo
Post# of 253280
Next 10
Followers 839
Posts 120534
Boards Moderated 18
Alias Born 09/05/2002

Re: DewDiligence post# 137995

Monday, 05/21/2012 1:10:00 PM

Monday, May 21, 2012 1:10:00 PM

Post# of 253280
FDA briefing docs for Xarelto in ACS:

http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm304754.htm

http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm285415.htm

The panel meeting is 5/23/12; the PDUFA date is in late June. Note that JNJ has submitted a separate Xarelto NDA for the (partially overlapping) indication of PCI secondary to ACS (#msg-75391993).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.